Plain-English translation of NCT07636148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study tracks patients who receive minimally invasive cancer treatments—such as targeted heating, catheter-based therapy, or other image-guided procedures—for solid tumors in the liver, kidney, lung, or bone. The study uses a newer type of imaging technology called spectral angio-CT, which combines real-time X-ray imaging with high-resolution CT scans to help doctors see tumors more clearly and guide treatment more precisely. All procedures are performed as standard clinical care, and the study simply collects data to learn whether this advanced imaging approach improves treatment outcomes.
Minimally invasive cancer treatments are gentler than surgery and help patients recover faster, but doctors want to know if newer imaging technology can make these procedures even more accurate and effective. This registry will help researchers understand how well spectral angio-CT imaging works in real-world clinical practice across multiple hospitals.
You likely qualify if…
You likely don't qualify if…
You will receive your scheduled minimally invasive cancer treatment exactly as your doctor has planned—no changes to your treatment or follow-up care. The only difference is that researchers will collect data about your procedure, imaging, and outcomes using the spectral angio-CT imaging system. Your doctors will continue to monitor you after treatment as they normally would, and this information will be added to a registry to help improve future cancer care.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
France
Netherlands